The Cooper Companies, Inc. · NASDAQ:COO
The Cooper Companies — Cooper Companies — Merger or Acquisition (September 2017)
9 slides from The Cooper Companies's merger presentation, Sep 12, 2017
Slide 1: Acquisition of PARAGARD IUD from Teva
Acquisition of PARAGARD® IUD from Teva September 11, 2017 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Forward-Looking Statements This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other
Slide 3: Acquisition of PARAGARD from Teva: Transaction Highlights
Acquiring the Global Rights and Business of the PARAGARD Intrauterine Device (IUD) from Teva Pharmaceutical Industries Ltd., for $1.1B cash Transaction expected to close by calendar year end 20171 Delivers compelling financial benefits TTM revenue of approx. $168 million as of 6/30/17, mid-single-di
Slide 4: Strategic Highlights: Great market and strategic fit
Great market – IUDs represent a large and growing segment of the contraceptive market IUD use has grown considerably in recent years in the U.S. but still lags behind the rest of the world The American Congress of Obstetricians and Gynecologists (ACOG) strongly supports the expansion of IUD contrace
Slide 5: PARAGARD Overview
PARAGARD is the only hormone-free, long lasting, reversible contraceptive option available in the U.S. FDA approved in 1984, 10 years of contraceptive use, over 99% effective 100% of sales in U.S. (acquiring global rights and will evaluate OUS launch) Established U.S. market share of approx. 16% Ope
Slide 6: IUD Market Overview
Total U.S. IUD Market: approx. $1 billion Non-Hormonal: approx. 16% of market (PARAGARD is the only option available, 10-year indication) Hormonal: approx. 84% of market Bayer: market leader with approx. 97% share Mirena: FDA approved in 2000 (5-year indication) Allergan: approx. 3% share, FDA appro
Slide 7: Regulatory and Potential Future Competitive Product
IUD’s are regulated as a pharmaceutical product in the U.S. and thus must go through a much more onerous approval process than devices FDA guidance on approval study typically requires (1) 10,000 women months of use for one year approval and (2) 200 women per year of claimed use Potential future com
Slide 8: ACA and Contraceptives
Private Insurance Must cover at least one type of all 18 FDA-approved contraceptive methods for women as prescribed without cost sharing Must cover the copper IUD (PARAGARD) and at least one hormonal IUD at no cost to policy holders Medicaid Federal law requires Medicaid programs to cover family pla
Slide 9: Questions?
Gdper Questions? : Goper
Cooper Companies — Merger or Acquisition (September 2017) on 6ix